Compare NVAX & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | TNDM |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1996 | 2013 |
| Metric | NVAX | TNDM |
|---|---|---|
| Price | $10.09 | $21.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 19 |
| Target Price | $11.33 | ★ $27.05 |
| AVG Volume (30 Days) | ★ 4.2M | 2.7M |
| Earning Date | 05-20-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 309.76 | N/A |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $1,123,479,000.00 | $1,014,736,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | $12.14 |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | ★ 64.69 | 7.93 |
| 52 Week Low | $5.01 | $10.00 |
| 52 Week High | $11.85 | $29.65 |
| Indicator | NVAX | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 49.24 |
| Support Level | $7.81 | $19.66 |
| Resistance Level | $10.42 | $24.23 |
| Average True Range (ATR) | 0.73 | 1.18 |
| MACD | -0.02 | -0.34 |
| Stochastic Oscillator | 36.18 | 25.22 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.